PrediSurge develops PlanOp, a predictive software platform that uses pre-operative imaging to generate numerical models and patient-specific digital twins for vascular and structural heart disease interventions. The company holds 11 patents and focuses on simulating biomechanical behavior to rehearse standard and complex EVAR procedures and evaluate device implantation strategies. PrediSurge positions its product with a low‑tech UX accessible via web links or printable PDFs to fit into existing clinical workflows and works with medtech companies to offer the software as a premium service or to de-risk device development. In 2023 it raised a €6.5 million Series A, bringing total funding to €10.5 million, and secured CE certification. The company plans to deploy its software across Europe and is pursuing FDA clearance, while an academic paper on digital mitral‑valve simulation is forthcoming. R&D scaling is a priority as PrediSurge moves from hundreds to thousands of simulations annually.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2024